Drug Trial Radar · NCT00280566
Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
Last checked: Nov 20, 2026Latest source record: Mar 25, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
584
Actual
Start
Dec 2005
Primary completion
May 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 23, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8 consecutive weeks of symptom improvement on the regimen.
Conditions
- Bipolar Mania
- Bipolar Disorder
Interventions
PlaceboDrug
Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
Ziprasidone Oral CapsuleDrug
Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Intervention for a Mood Episode During Double Blind PeriodTime frame: Period 2: 24 weeks or time of early termination
Locations
107 sites in 13 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Scottsdale, Arizona
Pfizer Investigational Site
Little Rock, Arkansas
Pfizer Investigational Site
Costa Mesa, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
National City, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Diego, California
Pfizer Investigational Site
Temecula, California
Pfizer Investigational Site
Temecula, California
Pfizer Investigational Site
Altamonte Springs, Florida
Pfizer Investigational Site
Fort Lauderdale, Florida
Pfizer Investigational Site
Fort Myers, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Maitland, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
North Miami, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Tavares, Florida
Pfizer Investigational Site
Decatur, Georgia
Pfizer Investigational Site
Smyrna, Georgia
Pfizer Investigational Site
Honolulu, Hawaii
Pfizer Investigational Site
Des Plaines, Illinois
Pfizer Investigational Site
Libertyville, Illinois
Pfizer Investigational Site
Naperville, Illinois
Pfizer Investigational Site
Naperville, Illinois
Pfizer Investigational Site
Oak Brook, Illinois
Pfizer Investigational Site
Schaumburg, Illinois
Pfizer Investigational Site
Terre Haute, Indiana
Pfizer Investigational Site
Topeka, Kansas
Pfizer Investigational Site
Wichita, Kansas
Pfizer Investigational Site
Lexington, Kentucky
Pfizer Investigational Site
Owensboro, Kentucky
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Rockville, Maryland
Pfizer Investigational Site
Pittsfield, Massachusetts
Pfizer Investigational Site
Taunton, Massachusetts
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.